Autologous dendritic cell vaccine (DC/PC3), Rockefeller University

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAutologous dendritic cell vaccine (DC/PC3), Rockefeller University

Drug Alias NameDC/PC3DC/LNCaP

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesThe Rockefeller University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe Rockefeller University

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A